Work

BCL-2-Interacting Mediator of Cell Death (Bim) is a Novel Biomarker for Response to Anti-PD-1 Therapy in Patients with Advanced Melanoma

Year: 2016

Type: editorial

Source: Immunotherapy

DOI: 10.2217/imt-2016-0100

Authors: Roxana S Dronca, Aaron S Mansfield, Sean S Park, Haidong Dong

Institution: Mayo Clinic

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: National Institutes of Health, National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Center for Advancing Translational Sciences

Awards: Role of Bim and soluble B7-H1 in monitoring T cell responses to anti-PD-1 therapy in melanoma, Functional B7-H1 expressed by T cells, Mayo Clinic Center for Clinical and Translational Science (CCaTS), A Phase II Evaluation of SABR in Oligometastatic Castration-Refractory Prostate Cancer and Immunogenicity of SABR, Paul Calabresi Program in Clinical/Translational Research at Mayo Clinic

OpenAlex ID: W2539528118

Cites: 14

Cited by: 8

Related to: 10